AnalystsSilvan TuerkcanSilvan Tuerkcan's Stock Forecasts
AnalystsSilvan Tuerkcan
Analyst Ranking
Top 5%
#244 out of 5154 analysts
Average Return
+17.24%
Win Rate
46%88 out of 192
Risk vs Reward
Poor
Good
Silvan Tuerkcan's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Terns Pharmaceuticals IncTERN | +1,483.76% | $2.71 | $42.92 | 2025-04-20 - 2025-12-16 | Buy |
Terns Pharmaceuticals IncTERN | +472.27% | $7.50 | $42.92 | 2025-10-22 - 2025-12-16 | Buy |
Nuvation Bio IncNUVB | +360.64% | $1.88 | $8.66 | 2025-06-24 - 2025-12-16 | Buy |
Intellia Therapeutics IncNTLA | +352.88% | $13.35 | $60.46 | 2020-02-27 - 2021-02-26 | Buy |
Logicbio Therapeutics IncLOGC2 | +345.16% | $0.47 | $2.07 | 2022-05-09 - 2022-11-15 | Buy |
Silvan Tuerkcan Analyst Color
Get additional color on Silvan Tuerkcan's coverage of popular stocks
Silvan Tuerkcan's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Terns Pharmaceuticals IncTERN | 15 | Buy | $57.00 | +32.81% | Maintains | 6 days ago |
Nuvation Bio IncNUVB | 5 | Buy | $10.00 | +15.47% | Maintains | a month ago |
Engene Holdings IncENGN | 5 | Buy | $21.00 | +152.40% | Maintains | a month ago |
Intellia Therapeutics IncNTLA | 10 | Buy | $21.00 | +130.26% | Maintains | a month ago |
Taysha Gene Therapies IncTSHA | 14 | Buy | $8.00 | +37.46% | Maintains | a month ago |
Benitec Biopharma IncBNTC | 14 | Buy | $22.00 | +77.28% | Maintains | a month ago |
Jasper Therapeutics IncJSPR | 7 | Buy | $6.00 | +250.88% | Maintains | 3 months ago |
Phreesia IncPHR | 1 | Buy | $34.00 | +107.95% | Maintains | 3 months ago |
Ideaya Biosciences IncIDYA | 2 | Buy | $45.00 | +33.10% | Maintains | 3 months ago |
Exelixis IncEXEL | 21 | Buy | $50.00 | +20.19% | Reiterates | 5 months ago |
Crispr Therapeutics AgCRSP | 15 | Buy | $86.00 | +53.65% | Reiterates | 6 months ago |
Solid Biosciences IncSLDB | 3 | Buy | $15.00 | +157.73% | Reiterates | 6 months ago |
Prime Medicine IncPRME | 3 | Buy | $6.00 | +54.64% | Maintains | 7 months ago |
Foghorn Therapeutics IncFHTX | 3 | Buy | $9.00 | +100.89% | Reiterates | 7 months ago |
Vor Biopharma IncVOR | 12 | Hold | $120.00 | +658.53% | Downgrades | 7 months ago |
Acrivon Therapeutics IncACRV | 5 | Buy | $17.00 | +602.48% | Reiterates | 9 months ago |
Elevation Oncology IncELEV | 7 | Hold | $7.00 | +1,817.81% | Downgrades | 9 months ago |
Context Therapeutics IncCNTX | 1 | Buy | $4.00 | +263.64% | Initiates Coverage On | a year ago |
Relay Therapeutics IncRLAY | 10 | Buy | $21.00 | N/A | Reiterates | a year ago |
Macrogenics IncMGNX | 10 | Buy | $8.00 | N/A | Maintains | a year ago |
Cellectis SaCLLS | 6 | Buy | $6.00 | N/A | Reiterates | 2 years ago |
Notable Labs LtdNTBLQ | 3 | Buy | $9.00 | N/A | Reiterates | 2 years ago |
Mondaycom LtdMNDY | 3 | Buy | $280.00 | N/A | Maintains | 2 years ago |
Mirati Therapeutics IncMRTX | 8 | Buy | $82.00 | N/A | Maintains | 2 years ago |
Generation Bio CoGBIO | 6 | Buy | $70.00 | N/A | Reiterates | 3 years ago |
Two Harbors Investment CorpTWO | 1 | Buy | $18.00 | N/A | Maintains | 3 years ago |
Logicbio Therapeutics IncLOGC2 | 3 | Buy | $3.00 | N/A | Maintains | 4 years ago |
Turning Point Therapeutics IncTPTX | 2 | Hold | N/A | N/A | Downgrades | 4 years ago |
Constellation Pharmaceuticals IncCNST | 1 | Hold | N/A | N/A | Downgrades | 5 years ago |
Seagen IncSGEN | 2 | Buy | $200.00 | N/A | Maintains | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.